As of April 29, 2025, MAIA Biotechnology (MAIA) has a market cap of $60.358 million USD. According to our data, MAIA Biotechnology is ranked No.7984 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 29, 2025 | $60.36 M |
16.54%
|
Dec 31, 2024 | $51.79 M |
69.23%
|
Dec 29, 2023 | $30.60 M |
-66.67%
|
Dec 30, 2022 | $91.81 M |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Eli Lilly
LLY
|
$797.31 B |
0.011 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$375.44 B |
0.012 M
|
![]() USA
|
![]() AbbVie
ABBV
|
$343.59 B |
0.230 B
|
![]() USA
|
![]() Novo Nordisk
NVO
|
$289.63 B |
71.297 B
|
![]() Denmark
|
![]() Novo Nordisk A/S
NOVO-B.CO
|
$277.07 B |
63.951 B
|
![]() Denmark
|
![]() Roche
ROG.SW
|
$263.24 B |
40.907 B
|
![]() Switzerland
|
![]() Novartis
NVS
|
$225.97 B |
0.161 B
|
![]() Switzerland
|
![]() AstraZeneca
AZN
|
$221.12 B |
0.008 M
|
![]() UK
|
![]() Merck
MRK
|
$212.01 B |
-0.001 M
|
![]() USA
|
![]() Thermo Fisher Scientific
TMO
|
$159.05 B |
0.003 M
|
![]() USA
|
![]() Amgen
AMGN
|
$152.20 B |
0.126 B
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$132.39 B |
-0.001 M
|
![]() USA
|
![]() Pfizer
PFE
|
$130.73 B |
-0.001 M
|
![]() USA
|
![]() Sanofi
SNY
|
$128.86 B |
0.003 M
|
![]() France
|
![]() Vertex Pharmaceuticals
VRTX
|
$127.64 B |
0.004 M
|
![]() USA
|
![]() Bristol-Myers Squibb
BMY
|
$98.62 B |
0.002 M
|
![]() USA
|
![]() Chugai Pharmaceutical
4519.T
|
$92.78 B |
0.001 M
|
![]() Japan
|
![]() CVS Health
CVS
|
$81.97 B |
-0.002 M
|
![]() USA
|
![]() GlaxoSmithKline
GSK
|
$77.05 B |
0.003 M
|
![]() UK
|
![]() CSL
CSL.AX
|
$76.39 B |
0.355 B
|
![]() Australia
|
Market Cap | = | MAIA Stock Price | * | MAIA Shares Outstanding |
= | $2.04 | * | 29.59 M | |
= | $60.36 M |